NCT00880867终止1 期
A Phase I Study of Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Toxicity (DLT)
研究概览
简要总结
The primary objective of this study is to evaluate the safety of intratumoral Polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC)(Hiltonol®) in addition to low-dose local radiotherapy for adult patients with low grade lymphomas, including follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and cutaneous T-cell lymphoma. The secondary endpoints are response rate, immune responses, and durability of responses as well as generation of antiinflammatory response at sites of tumor involvement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years of age.
- •Patients must have biopsy confirmed low-grade B-cell lymphoma (follicular, marginal zone, or small cell/chronic lymphocytic leukemia) or mycosis fungoides. B-cell lymphoma patients must have failed at least one prior therapy (chemotherapy or immunotherapy) or mycosis fungoides patients failed at least 1 topical or systemic treatment.
- •Patients must have at least one accessible tumor site that can be injected with poly-ICLC.
- •Patients must have measurable disease other than the injection site.
- •Patients must have a Karnofsky performance status of at least 70%.
- •Patients must have adequate hematologic, renal and liver function (i.e., absolute neutrophil count at least 1500/mm3, Platelets at least 100,000/mm3, creatinine no more than 1.7 mg/dl, total bilirubin no more than 1.5 mg/dl, transaminases no more than 4 times above the upper limits of the institutional normal).
- •Patients must be able to provide written informed consent.
- •Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. While animal testing has been negative, the anti-proliferative activity of this experimental drug may theoretically be harmful to the developing fetus or nursing infant.
- •Required washout period for prior therapy:
- •Topical therapy: 2 weeks.
- •Chemotherapy: 4 weeks
- •Radiotherapy: (including phototherapy): 4 weeks 13 of 26
- •Biological therapies: 4 weeks
- •Other investigational therapy: 4 weeks
- •Rituximab: 12 weeks
排除标准
- •Any history of autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, autoimmune hemolytic anemia, pure red cell aplasia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.
- •Off nucleoside or bendustine therapy for a minimum of 6 months
- •Prior treatment with Campath
- •Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active, prior treatment, or both).
- •Patients with active infection or with a fever > 38.5°C within three days prior to the first scheduled treatment.
- •CNS metastases.
- •Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
- •Current anticoagulant therapy (ASA no more than 325 mg/day allowed).
- •Significant cardiovascular disease (i.e., NYHA class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
- •Pregnant or lactating.
- •Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.
研究组 & 干预措施
Poly-ICLC
Experimental
Poly-ICLC plus low dose local radiation.
干预措施: Poly-ICLC (Drug)
结局指标
主要结局
Toxicity (DLT)
时间窗: Days 1 through 4 during weeks 1, 2, 3, 4, and 8
次要结局
- Tumor Response(Weeks 1 through 4, 8, 12, 16, and q3 months thereafter)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the SkinSarcoma of the SkinBasal Cell Cancer of the SkinBreast CancerMelanomaNCT01984892Nina Bhardwaj8
已完成
2 期
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)Head and Neck Squamous Cell Carcinoma (HNSCC)NCT04220866Merck Sharp & Dohme LLC18
进行中（未招募）
1 期
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeNon Small Cell Lung CancerMetastatic MelanomaMetastatic Renal Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT03474497Megan Daly, MD18
终止
1 期
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid TumorsSolid Tumor, AdultNCT03992326Centre Hospitalier Universitaire Vaudois6
终止
1 期
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)Metastatic MelanomaNCT01082887Nantes University Hospital18